Skip to main content

RECURSION PHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RXRX$3.81+8.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Exhibit Index:

Incorporated by Reference
Exhibit number · Description · Form · File No. · Exhibit No. · Filing Date · Filed / Furnished Herewith
2.1*Transaction Agreement by and between Recursion Pharmaceuticals, Inc. and Exscientia plc dated as of August 8, 2024.8-K001-403232.1August 8, 2024
3.1Amended and Restated Certificate of Incorporation of Recursion Pharmaceuticals, Inc.8-K001-403233.1April 21, 2021
3.2Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc.8-K001-403233.1January 31, 2024
4.1Specimen Class A common stock certificate of the Registrant.S-1/A333-2545764.2April 15, 2021
4.2Exchangeable Share Support Agreement, dated May 8, 2023.S-3ASR333-2722814.2May 30, 2023
4.3Registration Rights Agreement, dated October 24, 2022, by and among the Company and the Purchasers.8-K001-4032310.2October 25, 2022
4.4Registration Agreement, dated May 16, 2023, by and among the Registrant, Valence Discovery, Inc., and certain shareholders of Valence Discovery, Inc.S-3ASR333-2722814.3May 30, 2023
4.5Registration Agreement, dated May 25, 2023, by and among the Registrant, Recursion Canada Inc., and certain shareholders of Cyclica Inc.8-K001-403234.1June 9, 2023
4.6Registration Rights Agreement, dated July 11, 2023, by and among the Registrant and NVIDIA.8-K001-4032310.2July 12. 2023
10.1Form of Voting and Support Agreement.8-K001-4032310.1August 8, 2024
10.2Form of Irrevocable Undertaking (Institutional).8-K001-4032310.2August 8, 2024
10.3Form of Irrevocable Undertaking (Individual).8-K001-4032310.3August 8, 2024
10.4Irrevocable Undertaking of Evotec SE dated August 28, 2024.8-K001-4032310.1August 28, 2024
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1**Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
101.INSXBRL Instance DocumentX
101.SCHXBRL Taxonomy Extension Schema DocumentX
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABXBRL Taxonomy Extension Label Linkbase DocumentX
101.PREXBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)X
*Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.
**The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.